- Home
- PTGX vs KRYS Comparison
PTGX vs KRYS Comparison
Compare PTGX & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | KRYS |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.3B |
| IPO Year | 2016 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PTGX | KRYS |
|---|---|---|
| Price | $88.83 | $250.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $90.56 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 1.0M | 315.3K |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 275.72 |
| EPS | 0.72 | ★ 6.66 |
| Revenue | $209,217,000.00 | ★ $373,164,000.00 |
| Revenue This Year | N/A | $36.14 |
| Revenue Next Year | $288.98 | $41.80 |
| P/E Ratio | $123.35 | ★ $37.72 |
| Revenue Growth | N/A | ★ 54.51 |
| 52 Week Low | $33.70 | $122.80 |
| 52 Week High | $96.54 | $255.00 |
Technical Indicators
Market Signals| Indicator | PTGX | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 72.52 |
| Support Level | $84.11 | $231.69 |
| Resistance Level | $90.00 | $255.00 |
| Average True Range (ATR) | 3.31 | 7.88 |
| MACD | -0.75 | 0.44 |
| Stochastic Oscillator | 38.05 | 89.16 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.